ABSOLUTE PASI REDUCTIONS IN A PHASE 2B TRIAL OF THE SELECTIVE ORAL TYK2 INHIBITOR, TAK-279, IN MODERATE-TO-SEVERE PLAQUE PSORIASIS

被引：0
|
作者：
Green, Lawrence [1 ]
Ferris, Laura [2 ]
Moore, Angela [3 ,7 ,8 ]
Zirwas, Matthew [4 ]
Zhao, Yiwei [5 ]
Blau, Jessamyn [5 ]
Zhang, Wenwen [5 ]
Uy, Jonathan [5 ]
Winkelman, Warren [5 ]
Vender, Ronald [6 ]
机构：
[1] George Washington Univ, Sch Med, Rockville, MD USA
[2] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA
[3] Baylor Univ, Med Ctr, Dallas, TX USA
[4] Dermatologists Greater Columbus, Columbus, OH USA
[5] Takeda Dev Ctr Amer Inc, Cambridge, MA USA
[6] Dermatrials Res Inc, Hamilton, ON, Canada
[7] Arlington Res Ctr, Arlington, TX USA
[8] Arlington Ctr Dermatol, Arlington, TX USA
来源：
ACTA DERMATO-VENEREOLOGICA | 2024年 / 104卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P-069
引用
收藏
页数：102
相关论文
共 50 条
  • [41] Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial
    Catlett, Ian M.
    Gao, Lu
    Hu, Yanhua
    Banerjee, Subhashis
    Krueger, James G.
    DERMATOLOGY AND THERAPY, 2024, 14 (10) : 2827 - 2839
  • [42] Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, vs. placebo and apremilast in moderate-to-severe plaque psoriasis: achievement of absolute Psoriasis Area and Severity Index thresholds in two phase III trials
    Warren, Richard B.
    Lebwohl, Mark
    Gooderham, Melinda
    Thaci, Diamant
    Foley, Peter
    Gottlieb, Alice B.
    Banerjee, Subhashis
    Hippeli, Lauren
    Kisa, Renata M.
    Griffiths, Christopher E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [43] Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis
    Mease, Philip J.
    Deodhar, Atul A.
    van der Heijde, Desiree
    Behrens, Frank
    Kivitz, Alan J.
    Neal, Jeffrey
    Kim, Jonghyeon
    Singhal, Shalabh
    Nowak, Miroslawa
    Banerjee, Subhashis
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (06) : 815 - 822
  • [44] Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial
    Ohtsuki, Mamitaro
    Okubo, Yukari
    Komine, Mayumi
    Imafuku, Shinichi
    Day, Robert M.
    Chen, Peng
    Petric, Rosemary
    Maroli, Allan
    Nemoto, Osamu
    JOURNAL OF DERMATOLOGY, 2017, 44 (08): : 873 - 884
  • [45] Deucravacitinib, an oral selective allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan and South Korea with moderate-to-severe plaque psoriasis: a phase III randomized clinical trial
    Zhang, Jianzhong
    Ding, Yangfeng
    Wang, Ping
    Li, Linfeng
    Pan, Weili
    Lu, Yan
    Cheng, Hao
    Jiang, Xian
    Ho, Ji-Chen
    Guo, Shuping
    Liu, Leona
    Chatterjee, Arkendu
    Kisa, Renata M.
    Banerjee, Subhashis
    BRITISH JOURNAL OF DERMATOLOGY, 2025, 192 (03) : 402 - 409
  • [46] FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis
    Ferris, Laura K.
    Bagel, Jerry
    Huang, Yu-Huei
    Pink, Andrew E.
    Tyring, Stephen K.
    Kokolakis, Georgios
    Delozier, Amy M.
    Li, Shu
    Shen, Yaung-Kaung
    Iaconangelo, Charles
    Ota, Takayuki
    Bissonnette, Robert
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2025, 92 (03) : 495 - 502
  • [47] PHASE 2B, LONG-TERM EXTENSION, DOSE-RANGING STUDY OF ORAL JNJ-77242113 FOR THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS: FRONTIER-2
    Ferris, Laura K.
    Bagel, Jerry
    Huang, Yu-Huei
    Pink, Andrew E.
    Tyring, Stephen
    Kokolakis, Georgios
    Delozier, Amy M.
    Li, Shu
    Shen, Yaung-Kaung
    Ota, Takayuki
    Bissonnette, Robert
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [48] Phase 2b, Long-term Extension, Dose-ranging Study of Oral JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis: FRONTIER-2
    Ferris, Laura K.
    Bagel, Jerry
    Huang, Yu-Huei
    Pink, Andrew E.
    Tyring, Stephen K.
    Kokolakis, Georgios
    DeLozier, Amy M.
    Kakaley, Daniel
    Li, Shu
    Shen, Yaung-Kaung
    Ota, Takayuki
    Bissonnette, Robert
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 589 - 591
  • [49] Exposure-efficacy response modelling of bms-986165, a selective oral tyrosine kinase 2 (TYK2) inhibitor, in a phase 2 study in psoriasis
    Girgis, I.
    Chimalakonda, A.
    Kundu, S.
    Throup, J.
    Banerjee, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 36 - 36
  • [50] Deucravacitinib, a Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Japanese Patients With Psoriasis: Absolute PASI Outcomes in a Phase 3 Trial
    Okubo, Yukari
    Imafuku, Shinichi
    Tada, Yayoi
    Ohtsuki, Mamitaro
    Shao, Yanqiu
    Colston, Elizabeth
    Napoli, Andrew
    Hippeli, Lauren
    Banerjee, Subhashis
    Morita, Akimichi
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB147 - AB147
12345